Urine Tumor Deoxyribonucleic Acid (DNA) Testing Global Market Report 2026

The urine tumor deoxyribonucleic acid (DNA) testing market size has grown rapidly in recent years. It will grow from $1.18 billion in 2025 to $1.36 billion in 2026 at a compound annual growth rate (CAGR) of 14.6%. The growth in the historic period can be attributed to increasing incidence of urinary cancers, adoption of pcr-based urine testing, advancements in sequencing technologies, growing awareness of early cancer detection, expansion of hospital diagnostic facilities.

The urine tumor deoxyribonucleic acid (DNA) testing market size is expected to see rapid growth in the next few years. It will grow to $2.36 billion in 2030 at a compound annual growth rate (CAGR) of 14.9%. The growth in the forecast period can be attributed to ai-driven urine dna analysis, development of multiplex and high-throughput assays, expansion of personalized medicine, integration with electronic health records, rising demand for non-invasive monitoring solutions. Major trends in the forecast period include non-invasive cancer monitoring, liquid biopsy advancements, ai-powered genetic analysis, high-sensitivity urine dna detection, integration with clinical decision support systems.

The rising prevalence of urological cancers is anticipated to drive the growth of the urine tumor deoxyribonucleic acid (DNA) testing market in the coming years. Urological cancers affect the urinary system and male reproductive organs, including the kidneys, bladder, prostate, and testes, and their incidence is increasing largely due to aging populations, as cancer risk rises with age. Urine tumor DNA testing supports the management of urological cancers by enabling non-invasive detection of cancer-specific genetic mutations in urine, facilitating early diagnosis, monitoring disease progression, and guiding personalized treatment plans. For example, in December 2025, according to Cancer Australia, an Australia-based government department, an estimated 28,868 new prostate cancer cases were reported, representing roughly 30% of all new cancer diagnoses among men. Therefore, the rising prevalence of urological cancers is expected to propel the urine tumor deoxyribonucleic acid (DNA) testing market.

Key companies operating in the urine tumor deoxyribonucleic acid (DNA) testing market are increasingly focused on developing advanced solutions such as urine-based liquid biopsy platforms to enable non-invasive cancer detection, improve diagnostic accuracy, and support personalized treatment planning. Urine-based liquid biopsy platforms are non-invasive diagnostic systems designed to detect and analyze tumor-derived DNA and other biomarkers from urine samples for cancer detection, monitoring, and disease progression assessment. For example, in September 2024, PreAnalytiX, a joint venture between QIAGEN, a Netherlands-based sample-to-insight provider, and Becton, Dickinson and Company, a US-based medical technology firm, launched a novel urine-based liquid biopsy solution designed to enable high-quality DNA stabilization and extraction for downstream molecular analyses. Developed to support both clinical and research applications, the platform features standardized urine collection, efficient DNA preservation, and compatibility with next-generation sequencing workflows, facilitating early cancer detection, accurate biomarker assessment, and improved patient management.

In October 2024, Pangea Laboratory, a US-based provider of urine-based tumor DNA testing services, partnered with Unilabs to broaden access to its Bladder CARE Assay. Through this partnership, the companies intend to make the Bladder CARE Assay available in Switzerland and throughout Europe, enabling non-invasive bladder cancer detection through urine tumor DNA testing. Unilabs is a Switzerland-based provider of advanced molecular cancer diagnostics, including liquid biopsy and molecular residual disease (MRD) testing, supporting wider adoption of innovative oncology diagnostics.

Major companies operating in the urine tumor deoxyribonucleic acid (DNA) testing market are Roche Diagnostics, Thermo Fisher Scientific Inc., Abbott Laboratories, Illumina Inc., QIAGEN N.V., Bio-Techne Corporation, NeoGenomics Laboratories Inc., Freenome Holdings Inc., MDxHealth SA, Biodesix Inc., Sysmex Inostics GmbH, Pacific Edge Limited, Apostle Inc., Lucence Diagnostics, Pangea Laboratory, Nucleix Ltd, Genomica Lab, Vesica Health, Biocept Inc., Promis Diagnostics Inc.

North America was the largest region in the urine tumor deoxyribonucleic acid (DNA) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the urine tumor deoxyribonucleic acid (DNA) testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the urine tumor deoxyribonucleic acid (DNA) testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The urine tumor deoxyribonucleic acid (DNA) testing market consists of revenues earned by entities by providing services such as data interpretation, reporting and consultation, and quality control and assurance. The market value includes the value of related goods sold by the service provider or included within the service offering. The urine tumor deoxyribonucleic acid (DNA) testing market includes sales of storage tubes, sample transport containers, and analysis instruments. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Urine tumor DNA testing is a non-invasive diagnostic method that analyzes DNA fragments released by cancer cells into the urine. It helps detect genetic mutations and alterations associated with tumor development and progression, supporting cancer detection, recurrence monitoring, and assessment of treatment response.

The key technologies of urine tumor DNA testing include PCR-based methods, next-generation sequencing, and others. PCR-based methods amplify specific DNA or RNA sequences for detection, analysis, or research purposes. Product types include assay kits, instruments, and services. Applications include bladder, prostate, kidney, and other cancers, compatible with sample types such as first-morning urine, random urine samples, and catheterized urine samples. End users include hospitals, diagnostic laboratories, research institutes, and other organizations.

Tariffs have affected the urine tumor DNA testing market by increasing the cost of imported instruments, assay kits, and sequencing equipment. This impact is most pronounced in segments such as instruments and assay kits, particularly in regions like North America and Europe that rely heavily on imports for advanced diagnostics. While tariffs have raised costs, they are also incentivizing local manufacturing and innovation, encouraging the development of cost-effective and domestically produced solutions, thereby supporting long-term market growth.

The urine tumor deoxyribonucleic acid (DNA) testing market research report is one of a series of new reports that provides urine tumor deoxyribonucleic acid (DNA) testing market statistics, including urine tumor deoxyribonucleic acid (DNA) testing industry global market size, regional shares, competitors with a urine tumor deoxyribonucleic acid (DNA) testing market share, detailed urine tumor deoxyribonucleic acid (DNA) testing market segments, market trends and opportunities, and any further data you may need to thrive in the urine tumor deoxyribonucleic acid (DNA) testing industry. This urine tumor deoxyribonucleic acid (DNA) testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

This product will be delivered within 1-3 business days.